Related Experiment Video
Updated: Sep 16, 2025
Differentiating Chondrocytes from Peripheral Blood-derived Human Induced Pluripotent Stem Cells
Published on: July 18, 2017
The Effects of Tocilizumab on Inflammatory and Differentiation Pathways in Primary Human Chondrocytes: A
Bugrahan Regaip Kilinc1, Feyza Kostak2, Omer Faruk Yilmaz3
1Department of Biology, Institute of Natural and Applied Sciences, Namık Kemal University, Tekirdag, Turkey.
Introduction:
This study investigates the effects of Tocilizumab, an interleukin-6 (IL-6) receptor inhibitor, on human primary chondrocyte cells, focusing on bone morphogenetic protein 2 (BMP-2), hypoxia-inducible factor 1-alpha (HIF-1α), interleukin-1 beta (IL-1β), SRY-box transcription factor 9 (SOX-9), and IL-6 genes.
Methods:
Combining bioinformatic and experimental approaches, we assessed Tocilizumab's impact on inflammatory signaling pathways, cellular differentiation, and viability. Reactome and Gene Ontology (GO) enrichment analyses revealed the involvement of interleukin signaling, BMP, and mitogen-activated protein kinase (MAPK) pathways.
Results:
Protein-protein interaction (PPI) network analysis indicated strong interactions among the studied genes, with BMP-2 and SOX-9 identified as central nodes. Western blot analysis demonstrated a 71% reduction in SOX-9, a 55% reduction in HIF-1α, and an 81% reduction in BMP-2 expression levels by day 15. Conversely, IL-1β levels decreased by 67% after prolonged treatment. MTT assays showed a 27.7% reduction in cell viability at day 15 compared to controls. Despite these changes, staining analyses confirmed preserved cell membrane integrity and nuclear morphology, indicating minimal cytotoxic effects.
Conclusion:
These findings highlight Tocilizumab's role in modulating inflammation and differentiation pathways in human primary chondrocytes. Further studies should explore the long-term effects of IL-6 blockade on cartilage remodeling and regenerative capacity in chronic inflammatory settings.
Insights
Tocilizumab, an IL-6 receptor inhibitor, significantly reduced SOX-9, HIF-1α, and BMP-2 expression in chondrocytes. While cell viability decreased slightly, minimal cytotoxic effects were observed, suggesting a role in modulating inflammation and differentiation.
Area of Science:
- Cell Biology
- Immunology
- Biochemistry
Background:
- Investigates Tocilizumab's effects on human primary chondrocytes.
- Focuses on key genes: BMP-2, HIF-1α, IL-1β, SOX-9, and IL-6.
Purpose of the Study:
- Assess Tocilizumab's impact on inflammatory signaling, cellular differentiation, and viability.
- Elucidate mechanisms involving interleukin, BMP, and MAPK pathways.
Main Methods:
- Combined bioinformatic and experimental approaches.
- Utilized Reactome and Gene Ontology enrichment analyses.
- Performed Western blot and MTT assays.
Main Results:
- Tocilizumab reduced SOX-9 (71%), HIF-1α (55%), and BMP-2 (81%) expression by day 15.
- IL-1β levels decreased by 67% with prolonged treatment.
- Cell viability reduced by 27.7%, with preserved cell integrity.
Conclusions:
- Tocilizumab modulates inflammation and differentiation in chondrocytes.
- Highlights potential for IL-6 blockade in cartilage remodeling.
- Suggests further research into long-term effects in chronic inflammation.
Related Concept Videos
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:16TGF - β Signaling Pathway